Business Description
Lanzhou Foci Pharmaceutical Co Ltd
NAICS : 325412
SIC : 2834
ISIN : CNE1000019W4
Share Class Description:
SZSE:002644: Class ACompare
Compare
Traded in other countries / regions
002644.China IPO Date
2011-12-22Description
Lanzhou Foci Pharmaceutical Co Ltd is a pharmaceutical company based in China. The company is engaged in the production and sales of Chinese traditional medicine. In addition to manufacturing, the company also conducts research to develop new herbal drugs. Its product portfolio consists of concentrated pills, granules, hard capsules, concentrated decoctions and medicinal wine. The products of the company are exported to more than 27 countries including the United States, Canada, Japan, Australian, Russia, Ukraine, among others.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 14.19 | |||||
| Equity-to-Asset | 0.71 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | 0.47 | |||||
| Interest Coverage | 232.93 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 4.57 | |||||
| Beneish M-Score | -2.8 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 20.3 | |||||
| 3-Year EBITDA Growth Rate | -8.5 | |||||
| 3-Year EPS without NRI Growth Rate | 39.3 | |||||
| 3-Year Book Growth Rate | 3.3 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 94.63 | |||||
| 9-Day RSI | 85.93 | |||||
| 14-Day RSI | 77.36 | |||||
| 6-1 Month Momentum % | -17.91 | |||||
| 12-1 Month Momentum % | -41.85 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.9 | |||||
| Quick Ratio | 1.9 | |||||
| Cash Ratio | 0.86 | |||||
| Days Inventory | 199.82 | |||||
| Days Sales Outstanding | 131.2 | |||||
| Days Payable | 168.12 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.38 | |||||
| Dividend Payout Ratio | 0.21 | |||||
| 3-Year Dividend Growth Rate | -5.9 | |||||
| Forward Dividend Yield % | 0.38 | |||||
| 5-Year Yield-on-Cost % | 0.98 | |||||
| Shareholder Yield % | 0.18 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 31.46 | |||||
| Operating Margin % | 8.83 | |||||
| Net Margin % | 4.39 | |||||
| FCF Margin % | 6.39 | |||||
| ROE % | 2.59 | |||||
| ROA % | 1.79 | |||||
| ROIC % | 4.57 | |||||
| 3-Year ROIIC % | 20.94 | |||||
| ROC (Joel Greenblatt) % | 3.83 | |||||
| ROCE % | 2.62 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 88.11 | |||||
| PE Ratio without NRI | 56.24 | |||||
| Shiller PE Ratio | 52.87 | |||||
| PEG Ratio | 14.06 | |||||
| PS Ratio | 3.9 | |||||
| PB Ratio | 2.29 | |||||
| Price-to-Tangible-Book | 2.41 | |||||
| Price-to-Free-Cash-Flow | 61 | |||||
| Price-to-Operating-Cash-Flow | 44.8 | |||||
| EV-to-EBIT | 63.24 | |||||
| EV-to-EBITDA | 63.24 | |||||
| EV-to-Revenue | 3.3 | |||||
| EV-to-FCF | 51.64 | |||||
| Price-to-Projected-FCF | 3.81 | |||||
| Price-to-DCF (Earnings Based) | 1.64 | |||||
| Price-to-DCF (FCF Based) | 4.9 | |||||
| Price-to-Median-PS-Value | 0.56 | |||||
| Price-to-Graham-Number | 2.46 | |||||
| Price-to-Net-Current-Asset-Value | 8.09 | |||||
| Earnings Yield (Greenblatt) % | 1.58 | |||||
| FCF Yield % | 1.64 | |||||
| Forward Rate of Return (Yacktman) % | 4.49 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Lanzhou Foci Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 1,036.355 | ||
| EPS (TTM) (Â¥) | 0.09 | ||
| Beta | 1.97 | ||
| Volatility % | 40.14 | ||
| 14-Day RSI | 77.36 | ||
| 14-Day ATR (Â¥) | 0.279576 | ||
| 20-Day SMA (Â¥) | 6.6905 | ||
| 12-1 Month Momentum % | -41.85 | ||
| 52-Week Range (Â¥) | 5.84 - 11.35 | ||
| Shares Outstanding (Mil) | 510.66 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Lanzhou Foci Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Lanzhou Foci Pharmaceutical Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Lanzhou Foci Pharmaceutical Co Ltd Frequently Asked Questions
What is Lanzhou Foci Pharmaceutical Co Ltd(SZSE:002644)'s stock price today?
The current price of SZSE:002644 is ¥7.93. The 52 week high of SZSE:002644 is ¥11.35 and 52 week low is ¥5.84.
When is next earnings date of Lanzhou Foci Pharmaceutical Co Ltd(SZSE:002644)?
The next earnings date of Lanzhou Foci Pharmaceutical Co Ltd(SZSE:002644) is .
Does Lanzhou Foci Pharmaceutical Co Ltd(SZSE:002644) pay dividends? If so, how much?
The Dividend Yield %  of Lanzhou Foci Pharmaceutical Co Ltd(SZSE:002644) is 0.38% (As of Today), Highest Dividend Payout Ratio of Lanzhou Foci Pharmaceutical Co Ltd(SZSE:002644) was 1.62. The lowest was 0.08. And the median was 0.1. The  Forward Dividend Yield % of Lanzhou Foci Pharmaceutical Co Ltd(SZSE:002644) is 0.38%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers